Discrepant alterations in main candidate genes among multiple primary melanomas

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Colombino, Maria ^a   Sini, MariaCristina ^a   Lissia, Amelia ^b   De Giorgi, Vincenzo ^c   Stanganelli, Ignazio ^d   Ayala, Fabrizio ^e   Massi, Daniela ^c   Rubino, Corrado ^f   Manca, Antonella ^a   Paliogiannis, Panagiotis ^b   Rossari, Susanna ^c   Magi, Serena ^d   Mazzoni, Laura ^d   Botti, Gerardo ^e   Capone, Mariaelena ^e   Palla, Marco ^e   Ascierto, Paolo A ^e   Cossu, Antonio ^b   Palmieri, Giuseppe ^a   Caraco C ^g   Chiarion Sileni, V ^g   Mozzillo, N ^g   Queirolo, P ^g   Rossi, C R ^g   Testori, A ^g   more..

^a CNR   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

^g Unit of Plastic Surgery University of Salerno ^*

Author keywords

Gene amplification; Melanomagenesis; Molecular classification; Multiple melanoma; Mutation analysis

Indexed keywords

B RAF KINASE; CYCLIN D; BRAF PROTEIN, HUMAN; CYCLIN D1; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER GROWTH; CKIT GENE; CONTROLLED STUDY; CYCLIND1 GENE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE PRIMARY MELANOMA; ONCOGENE; PATHOGENESIS; SOMATIC MUTATION; GENETICS; MIDDLE AGED; MUTATION;

ADULT; CYCLIN D1; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84900820504     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-117     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G. ESMO Guidelines Working Group: Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(Suppl 7):vii86-vii91.
3. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41:2040-2059. 10.1016/j.ejca.2005.03.034, 16125929.
4. Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006, 24:3172-3177. 10.1200/JCO.2006.06.1325, 16809740.
5. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004, 96:785-795. 10.1093/jnci/djh136, 15150307.
6. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005, 294:1647-1654. 10.1001/jama.294.13.1647, 16204664.
7. Murali R, Goumas C, Kricker A, From L, Busam KJ, Begg CB, Dwyer T, Gruber SB, Kanetsky PA, Orlow I, Rosso S, Thomas NE, Berwick M, Scolyer RA, Armstrong BK, . GEM Study Group Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol 2012, 19:1024-1033. 10.1245/s10434-011-2058-8, 3288399, 21913010, GEM Study Group.
8. Bower MR, Scoggins CR, Martin RC, Mays MP, Edwards MJ, Reintgen DS, Ross MI, Urist MM, Noyes RD, Sussman JJ, Hagendoorn LJ, Stromberg AJ, McMasters K. Second primary melanomas: incidence and outcome. Am Surg 2010, 76:675-681.
9. De Giorgi V, Rossari S, Papi F, Gori A, Alfaioli B, Grazzini M, Crocetti E, Verdelli A, Foo CW, Lotti T. Multiple primary melanoma: the impact of atypical naevi and follow up. Br J Dermatol 2010, 163:1319-1322. 10.1111/j.1365-2133.2010.09961.x, 20670298.
10. Hwa C, Price LS, Belitskaya-Levy I, Ma MW, Shapiro RL, Berman RS, Kamino H, Darvishian F, Osman I, Stein JA. Single versus multiple primary melanomas: old questions and new answers. Cancer 2012, 118:4184-4192. 10.1002/cncr.27407, 22246969.
11. Moscarella E, Rabinovitz H, Puig S, Zalaudek I, Oliviero MC, Brown L, Alarcon I, Malvehy J, Longo C, Formisano D, Carrera C, Badenas C, Piana S, Albertini G, Pellacani G, Argenziano G. Multiple primary melanomas: do they look the same?. Br J Dermatol 2013, 168:1267-1272. 10.1111/bjd.12260, 23374221.
12. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
13. Fecher LA, Amaravadi RK, Flaherty KT. The MAPK pathway in melanoma. Curr Opin Oncol 2008, 20:183-189. 10.1097/CCO.0b013e3282f5271c, 18300768.
14. Pritchard AL, Hayward NK. Molecular pathways: mitogen-activated protein kinase pathway mutations and drug resistance. Clin Cancer Res 2013, 19:2301-2309. 10.1158/1078-0432.CCR-12-0383, 23406774.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
16. Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 2011, 24:902-921. 10.1111/j.1755-148X.2011.00908.x, 21914141.
17. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C. Mutation of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712. 10.1136/gut.52.5.706, 1773624, 12692057.
18. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Taran-tino L, Sordelli I, Agresti M, Abbruzzese A, Caraglia M, Palmieri G. BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis 2012, 3:e259. 10.1038/cddis.2011.136, 3270270, 22258409.
19. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra R. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013, 15:220-226. 10.1016/j.jmoldx.2012.10.002, 23273605.
20. Heinzerling L, Baiter M, Kühnapfel S, Schuler G, Keikavoussi P, Agaimy A, Kiesewetter F, Hartmann A, Schneider-Stock R. Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer 2013, 109:2833-2841. 10.1038/bjc.2013.622, 24196789.
21. Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, Laurent-Puig P, . BRAF EQA Group Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer 2013, 13:472. 10.1186/1471-2407-13-472, 3852250, 24119386, BRAF EQA Group.
22. Sullivan RJ, Flaherty K. MAP kinase signaling and inhibition in melanoma. Oncogene 2013, 32:2373-2379. 10.1038/onc.2012.345, 22945644.
23. Palmieri G, Capone ME, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Transl Med 2009, 7:86. 10.1186/1479-5876-7-86, 2770476, 19828018.
24. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003, 22:3092-3098. 10.1038/sj.onc.1206461, 12789286.
25. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147. 10.1056/NEJMoa050092, 16291983.
26. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346. 10.1200/JCO.2006.06.2984, 16908931.
27. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008, 7:2876-2883. 10.1158/1535-7163.MCT-08-0431, 2651569, 18790768.
28. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, et al. Future perspectives in melanoma research Meeting report from the " Melanoma Bridge Napoli, December 2nd-4th 2012" . J Transl Med 2013, 11:137. 10.1186/1479-5876-11-137, 3681569, 23731854.
29. Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Mod Pathol 2009, 22:1367-1378. 10.1038/modpathol.2009.109, 19633643.
30. Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV, Rizos H. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 2013, 12:1332-1342. 10.1158/1535-7163.MCT-13-0011, 23645591.
31. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14:6821-6828. 10.1158/1078-0432.CCR-08-0575, 18980976.
32. Kong Y, Si L, Zhu Y, Xu X, Corless CL, Flaherty KT, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lu A, Guo J. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011, 17:1684-1691. 10.1158/1078-0432.CCR-10-2346, 21325067.
33. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013, 31:3182-3190. 10.1200/JCO.2012.47.7836, 23775962.
34. Johnson TM, Hamilton T, Lowe L. Multiple primary melanomas. J Am Acad Dermatol 1998, 39:422-427. 10.1016/S0190-9622(98)70318-4, 9738776.
35. Carli P, De Giorgi V, Chiarugi A, Stante M, Giannotti B. Multiple synchronous cutaneous melanomas: implications for prevention. Int J Dermatol 2002, 41:583-585. 10.1046/j.1365-4362.2002.01605.x, 12358828.
36. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998, 16:670-682.
37. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006, 355:51-65. 10.1056/NEJMra052166, 16822996.
38. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet 2009, 374:362-365. 10.1016/S0140-6736(09)61397-0, 19647595.
39. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, Cibulskis K, Kryukov G, Hodis E, Lawrence DP, Fisher S, Getz G, Gabriel SB, Carter SL, Flaherty KT, Wargo JA, Garraway LA. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014, 4:61-68. 10.1158/2159-8290.CD-13-0631, 24265154.
40. Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, Fonsatti E, Maio M, Botti G, Caracò C, Mozzillo N, Ascierto PA, Cossu A, Palmieri G. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med 2013, 11:202. 10.1186/1479-5876-11-202, 3765741, 23987572.
41. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011, 164:776-784. 10.1111/j.1365-2133.2010.10185.x, 21166657.
42. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002, 62:3200-3206.
43. Glatz-Krieger K, Pache M, Tapia C, Fuchs A, Savic S, Glatz D, Mihatsch M, Meyer P. Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. Virchows Arch 2006, 449:328-333. 10.1007/s00428-006-0167-8, 16523260.
44. Gast A, Scherer D, Chen B, Bloethner S, Melchert S, Sucker A, Hemminki K, Schadendorf D, Kumar R. Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer 2010, 49:733-745. 10.1002/gcc.20785, 20544847.
45. Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini MC, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30:2522-2529. 10.1200/JCO.2011.41.2452, 22614978.
46. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, Takata M. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011, 104:464-468. 10.1038/sj.bjc.6606072, 3049568, 21224857.